Healthcare Industry News: HSMN NewsFeed
News Release - March 11, 2020
INVOcell Appoints Yve Lyppens as Director Business Development Asia PacificSARASOTA, Fla., March 11, 2020 -- (Healthcare Sales & Marketing Network) -- INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company focused on treating infertility with its FDA-cleared INVOcell® product, today announced that Yve Lyppens has been appointed Director Business Development Asia Pacific. Based in Hong Kong, Mr. Lyppens will work with the company's COO and VP of Business Development, Michael Campbell, in developing the Company's sales and distribution network throughout Asia.
Yve Lyppens comes to INVO Bioscience with more than a decade of experience in sales and distribution management. From 2016 to the present, he served as Asia Pacific Sales Director for Biomedic Hong Kong Ltd., a medical device distributor in Mainland China. Prior to that, from 2011 to 2016, Mr. Lyppens served as a Director, Shareholder and Sales Manager at F Care Systems Hong Kong Ltd., a developer and exporter of medical aesthetics equipment.
Steve Shum, CEO of INVO Bioscience, commented, "We are pleased to have Yve Lyppens join the INVO Bioscience business development operations group. He is an established sales and marketing professional in the Asian region, having established distribution networks across Asia and Australia for other medical device companies. Yve's ability to execute strategies individually with multiple distributors, including the development of workshops that focus on distributor training in sales and product positioning, should benefit us as we execute our INVOcell expansion through the region. Finally, Yve has a strong understanding of product registration in the region that should help accelerate our go to market timelines. I look forward to Yve's contributions as we execute on our mission of advancing the treatment of infertility worldwide."
INVOcell is the first intravaginal culture device used for the incubation of eggs and sperm during fertilization and early embryo development using the women's body for natural incubation as an alternative to traditional IVF that uses incubators for fertilization and embryo.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Source: INVO Bioscience
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.